Bibliographic citations
Peralta, D., (2021). Accesibilidad de medicamentos oncológicos mediante el sistema de licencias obligatorias: un análisis a partir del caso Keytruda [Pontificia Universidad Católica del Perú]. http://hdl.handle.net/20.500.12404/18809
Peralta, D., Accesibilidad de medicamentos oncológicos mediante el sistema de licencias obligatorias: un análisis a partir del caso Keytruda []. PE: Pontificia Universidad Católica del Perú; 2021. http://hdl.handle.net/20.500.12404/18809
@misc{renati/20720,
title = "Accesibilidad de medicamentos oncológicos mediante el sistema de licencias obligatorias: un análisis a partir del caso Keytruda",
author = "Peralta Cubas, Diego Rafael Jaime",
publisher = "Pontificia Universidad Católica del Perú",
year = "2021"
}
The purpose of this research is to analyze the problems of Keytruda, a drug that has been shown to have great benefits for the treatment of various types of cancer but that unfortunately is not easily accessible due to its low availability and high price. In this regard, the objective is to provide a legal solution that involves the implementation of a public policy whose ultimate goal is to protect the right to health and give priority to the public interest in this case. In order to achieve this, it is pertinent to carry out a weighting test to reconcile this need with the exclusive rights granted to Merck Sharp & Dohme (MSD), which is the holder of the respective patent. In this sense, the proposed analysis seeks to propose the system of compulsory licenses as the most appropriate way to solve the problems raised. Thus, our proposal is not only designed to provide a solution to the conflict in question, but also has a vocation to serve as a valid alternative in the current context of high costs of cancer treatments.
This item is licensed under a Creative Commons License